Maxcyte (MXCT) Liabilities and Shareholders Equity (2020 - 2026)

Maxcyte (MXCT) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $194.5 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $194.5 million, down 15.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $830.2 million (down 14.37% YoY), and the FY2025 annual result was $202.5 million, down 15.44% from the prior year.
• Liabilities and Shareholders Equity slipped to $194.5 million in Q1 2026 per MXCT's latest filing, from $202.5 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $291.0 million in Q1 2022 and troughed at $194.5 million in Q1 2026.
• A 5-year average of $252.9 million and a median of $257.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity soared 211.1% in 2022, then retreated 15.44% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $286.7 million in 2022, then declined by 6.41% to $268.3 million in 2023, then retreated by 10.74% to $239.5 million in 2024, then decreased by 15.44% to $202.5 million in 2025, then dropped by 3.97% to $194.5 million in 2026.
• Business Quant data shows MXCT's Liabilities and Shareholders Equity at $194.5 million in Q1 2026, $202.5 million in Q4 2025, and $213.5 million in Q3 2025.